Passage cuts 75% of workforce after FDA trial design request

Passage Bio Cuts Workforce After FDA Rejects Trial Design

Passage Bio is cutting approximately 75% of its workforce, impacting around 18 employees, to reduce operating expenses. This decision follows the FDA's requirement for a randomized controlled trial design for its lead candidate, PBFT02, in frontotemporal dementia with granulin mutations (FTD-GRN), rejecting the company's proposed single-arm trial. In response, Passage Bio is exploring strategic alternatives, including mergers, acquisitions, or asset sales, to maximize shareholder value. Despite these challenges, positive Phase 1/2 data for PBFT02 showed potential to slow neurodegeneration, with improvements in brain atrophy and plasma neurofilament levels, and durable progranulin elevation. The company reported $46.3 million in cash and cash equivalents as of December 31, expected to fund operations into Q1 2027.

• Passage Bio is implementing a significant workforce reduction of approximately 75%, affecting around 18 employees, to cut operating expenses. This move is projected to incur about $3.3 million in severance and exit costs. As of December 31, the company held $46.3 million in cash and cash equivalents, which it anticipated would sustain operations until the first quarter of 2027. This financial restructuring is a direct response to recent regulatory challenges and the need to conserve capital while evaluating future strategies.
• The FDA has mandated a randomized controlled trial design for Passage Bio's lead candidate, PBFT02, for frontotemporal dementia with granulin mutations (FTD-GRN). This decision, communicated after a Type C meeting, rejected the company's proposed single-arm trial design. CEO Will Chou highlighted the "ethical, logistical, and financial challenges" associated with this requirement, prompting the company to re-evaluate the entire clinical development program for PBFT02. This regulatory hurdle is a primary driver for the company's strategic shifts.
• Despite regulatory setbacks, Passage Bio reported encouraging data from its ongoing Phase 1/2 upliFT-D clinical trial for PBFT02 in FTD-GRN. The data indicated that PBFT02 may slow neurodegeneration, evidenced by improvements in brain atrophy and plasma neurofilament levels, which are key biomarkers of disease progression. Furthermore, the drug demonstrated durable and robust elevations in progranulin, its target protein, with emerging data suggesting similar efficacy at lower doses. These positive clinical findings offer a potential silver lining amidst the company's broader strategic re-evaluation.

FDA's RCT Mandate: A New Path for PBFT02 Trials

The available literature reveals limited completed clinical trial data for FTD-GRN, with most research focused on natural history studies and biomarker development. Current efforts center on establishing robust outcome measures and identifying therapeutic targets for future interventional studies.

The Unmet Need in Frontotemporal Dementia with GRN Mutations

Frontotemporal dementia caused by GRN mutations represents a significant therapeutic challenge, with no FDA-approved disease-modifying treatments currently available for this uniformly fatal neurodegenerative disorder. These conditions affect adults in their middle years and progress rapidly compared to other dementias, leaving patients without evidence-based targeted therapeutic options.

• Absence of approved therapeutics — No FDA-approved disease-modifying treatments exist for FTD-GRN, though multiple approaches targeting progranulin restoration are now in clinical trials

• Limited clinical trial success — A pilot phase II trial of amiodarone (200 mg/day) in five FTD-GRN patients showed no significant effect on peripheral GRN levels, and disease progression was unchanged compared to untreated patients

• Biomarker interpretation challenges — A more nuanced understanding of neurofilament light as a neurodegeneration biomarker is required for optimal patient stratification and treatment response assessment, accounting for its relationship to other pathophysiological markers across disease stages

• Complex genotype-phenotype relationships — More than 60 pathogenic GRN mutations have been reported with prominent phenotypic variability within and among affected families, making clinical management decisions challenging

• Mechanistic knowledge gaps — Poor understanding of how GRN mutations contribute to disease pathogenesis and neurodegeneration has hindered therapeutic development, with critical questions remaining about approaches like gene therapy

• Variable mutation-specific factors — Plasma progranulin concentrations vary by GRN mutation type, sex, and age, requiring consideration of these factors when interpreting biomarker data in clinical trials

Passage Bio Navigates Critical Crossroads After FDA Mandate

The recent regulatory decision impacting Passage Bio's lead candidate, PBFT02, sends a clear signal across the rare disease and gene therapy landscape. The FDA's insistence on a randomized controlled trial (RCT) for frontotemporal dementia with granulin mutations (FTD-GRN), rather than the proposed single-arm study, underscores a heightened bar for evidence generation, even for conditions with profound unmet medical needs. This move, while aimed at ensuring robust efficacy and safety data, significantly alters the development trajectory for PBFT02 and similar programs.

For Passage Bio, the immediate consequence is a dramatic restructuring, including a substantial workforce reduction, as the company grapples with the extended timelines and increased financial burden of an RCT. Research indicates that PBFT02 demonstrated promising early-stage results, showing potential to slow neurodegeneration, with improvements in brain atrophy and plasma neurofilament levels, alongside durable progranulin elevation. However, the path to market is now considerably longer and more complex.

This situation presents several critical implications and risks. The shift to an RCT introduces substantial financial risk, potentially exhausting the company's current cash runway, despite projections into Q1 2027. This necessitates a successful pursuit of strategic alternatives, such as mergers, acquisitions, or asset sales, to secure the necessary funding. Furthermore, the regulatory delay could open a window for competitors to advance their own therapies, potentially eroding PBFT02's future market position. The inherent complexity and higher statistical bar of an RCT also elevate the risk of trial failure, despite the encouraging early clinical signals.

Ultimately, this development highlights the delicate balance between accelerating access to innovative therapies for rare diseases and maintaining rigorous regulatory standards. While the FDA's stance aims to protect patients, it places immense pressure on small biotechs, potentially delaying life-changing treatments and reshaping investment strategies within the gene therapy sector. The future of PBFT02, and indeed Passage Bio, now hinges on successfully navigating these strategic and financial challenges.